AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develop treatments for rare, chronic, and infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company uses boron chemistry for its research and development initiatives. AN2 was incorporated in 2017 and is headquartered in Menlo Park, CA.